Validation of Circulating miRNA Biomarkers for Predicting Lymph Node Metastasis in Gastric Cancer

Kim, Shine Young; Jeon, Tae Yong; Choi, Chang In; Kim, Dae Hwan; Kim, Dong Heon; Kim, Gwang Ha; Ryu, Dong Yup; Lee, Bong Eun; Kim, Hyung Hoi

doi:10.1016/j.jmoldx.2013.04.004

Cited by 76 publications

(54 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In contrast to mRNAs and proteins, miRNAs are not involved in complex post-transcriptional and post-transcriptional modification. Considering the limitations of condition and time for tissue sampling (Freidin et al 2012), circulating miRNAs are optimal prog- nostic biomarkers for cancer (Sanfiorenzo et al 2013;Chen et al 2013b;Lin et al 2013;Greenberg et al 2013;Kim et al 2013). However, further studies should be conducted before miRNA can be extensively used in clinical applications.…”

Section: Discussionmentioning

confidence: 99%

“…The unique expression profile of circulating miRNA may function as the fingerprint of different diseases because miRNAs are highly stable in serum and plasma (Chen et al 2008). Circulating miRNA has been considered as a potential non-invasive biomarker in tumor diagnosis and prognosis (Sanfiorenzo et al 2013;Chen et al 2013b;Lin et al 2013;Greenberg et al 2013;Kim et al 2013;Rani et al 2013).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Serum Levels of miR-19b and miR-146a as Prognostic Biomarkers for Non-Small Cell Lung Cancer

Cao

et al. 2014

Tohoku J. Exp. Med.

View full text Add to dashboard Cite

MicroRNA (miRNA) is a type of small non-coding RNA molecule that has important roles in cancer initiation, promotion and progression by negatively regulating gene expression. In this study, we explored the role of miRNAs in the prognosis of patients with non-small cell lung cancer (NSCLC). The miRNA expression profiles were determined in 5 pairs of NSCLC and paracancerous tissues (3 adenocarcinomas and 2 squamous cell carcinomas). Aberrantly expressed miRNAs were validated by quantitative real-time PCR (qRT-PCR) in 61 pairs of NSCLC and paracancerous tissues. Differentially expressed miRNAs were further analyzed in sera from 94 healthy subjects and 94 advanced NSCLC patients receiving platinumbased chemotherapy. Three miRNAs (miR-19b, miR-146a, and miR-223) were significantly dysregulated in NSCLC tissues (P < 0.05). High miR-19b and low miR-146a expression in NSCLC tissues were associated with higher TNM stage, lymph node metastasis and poorer survival (P < 0.05). The serum levels of miR-19b in NSCLC patients were significantly higher (P < 0.001), whereas serum levels of miR-146a were significantly lower (P < 0.001), compared with those in controls. Serum levels of miR-19b and miR-146a were associated with overall survival of NSCLC patients (P < 0.05). Patients with low serum level of miR-19b and high serum level of miR-146a achieved a higher overall response rate and longer survival time (P < 0.05). These data suggest that miR-19b and miR-146a are potential biomarkers for the prediction of survival and response to chemotherapy in NSCLC.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Serum Levels of miR-19b and miR-146a as Prognostic Biomarkers for Non-Small Cell Lung Cancer

Cao

et al. 2014

Tohoku J. Exp. Med.

View full text Add to dashboard Cite

show abstract

“…In recent years, the roles of certain SNPs in the miRNA-coding regions and their effects on the risk of human gastric cancers have been extensively investigated (22). It has been demonstrated that SNPs in miRNA-coding regions are associated with gastric carcinogenesis and increased susceptibility to the development of gastric cancer (23,24). Better understanding of the association between these SNPS and the risk of gastric cancer may provide novel insights into the prevention and early diagnosis of human gastric cancer in high-risk populations and important guidelines for the management of this malignancy (25,26).…”

Section: Discussionmentioning

confidence: 99%

Lack of association of two common polymorphisms rs2910164 and rs11614913 with susceptibility to gastric cancer: A meta-analysis

Zhang¹,

Gao²,

Zhou³

et al. 2015

Turk J Gastroenterol

View full text Add to dashboard Cite

Background/Aims: MicroRNAs post-transcriptionally regulate the expression of their target genes and their function in a wide range of physiological pathways. Aberrant expression of microRNAs has been implicated in the development of human malignant tumors. Recent reports showed that two single nucleotide polymorphisms (SNPs), miR-146a rs2910164 and miR-196a2 rs11614913, are associated with increased risk of human gastric cancer. Nevertheless, results from the published reports are still inconsistent and inconclusive. Thus, we conducted this meta-analysis study to further evaluate the effects of these two SNPs on susceptibility to human gastric cancer. Materials and Methods: Using specific inclusion and exclusion criteria, we extracted data from selected studies that were identified from electronic databases, such as PubMed, Embase, and Wanfang. Odds ratio (ORs) and 95% CIs were then obtained to determine the impact of the two SNPs on susceptibility to human gastric cancer using the statistical software Stata. Results: We identified six studies on rs2910164 and five reports regarding rs11614913 for our meta-analysis. Our data demonstrated that the two SNPs rs2910164 and rs11614913 do not produce any effects on the risk of human gastric cancer under all genetic models. Conclusion: There is no significant association between rs2910164 and rs11614913 and the risk of human gastric cancer. However, future studies with large and homogeneous population of patients with gastric cancer and wellmatched controls are needed to validate these findings.

show abstract

“…Recently, several reports have highlighted the diagnostic and prognostic utility of serum or plasma-based miRNA levels, because tumorderived miRNAs are present in human circulation in remarkably stable forms that are protected from endogenous ribonuclease activity [5]. These studies suggest that serum or plasma miRNA-based assays may constitute accurate methods for the diagnosis and prognostic prediction of cancer, although, to date, only a few studies have specifically focused on the clinical significance of circulating miRNAs in patients with GC [6][7][8][9][10][11][12].…”

Section: Introductionmentioning

confidence: 99%

Circulating microRNA-203 predicts metastases, early recurrence, and poor prognosis in human gastric cancer

et al. 2015

View full text Add to dashboard Cite

Background Metastasis is a major cause of death in patients with gastric cancer (GC). MicroRNAs (miRNAs) relating to the epithelial-mesenchymal transition (EMT) control GC progression and metastasis. The aim of this study was to evaluate serum EMT-associated miRNAs for metastatic and prognostic noninvasive biomarkers in GC. Methods In the first step of this study (preliminary experiments), we selected candidate miRNAs associated with metastasis by analyzing the expression of the miR-200 family (miR-200a, miR-200b, miR-200c, miR-141, and miR-429) and miR-203 in serum samples from stage I (n = 12) and stage IV (n = 12) GC patients. The second phase involved the independent validation of candidate miRNAs in serum specimens from 130 patients with GC and 22 controls. Results Based on the preliminary experiments, miR-203 was selected as the candidate serum miRNA that was most closely associated with metastasis. Validation analysis revealed that serum miR-203 levels were significantly lower in stage IV than stage I-III GC patients. Serum miR-203 expression was significantly lower in GC patients with a higher T stage, vessel invasion, and lymph node, peritoneal, and distant metastases. Low expression of serum miR-203 was significantly associated with poor diseasefree and overall survival. Multivariate analysis revealed that low serum miR-203 expression was an independent predictive marker for lymph node, peritoneal, and distant metastases and a poor prognosis in patients with GC. Conclusions Serum miR-203 has the potential to serve as a noninvasive biomarker for prognosis and to predict metastasis in patients with GC.

show abstract

Validation of Circulating miRNA Biomarkers for Predicting Lymph Node Metastasis in Gastric Cancer

Cited by 76 publications

References 34 publications

Serum Levels of miR-19b and miR-146a as Prognostic Biomarkers for Non-Small Cell Lung Cancer

Serum Levels of miR-19b and miR-146a as Prognostic Biomarkers for Non-Small Cell Lung Cancer

Lack of association of two common polymorphisms rs2910164 and rs11614913 with susceptibility to gastric cancer: A meta-analysis

Circulating microRNA-203 predicts metastases, early recurrence, and poor prognosis in human gastric cancer

Contact Info

Product

Resources

About